HitChem published a Patent Watch highlighting newly released filings targets including APJ, JAK2, HSV, TNFα, and CDK2.

HitChem integrates advanced cheminformatics and cutting-edge language models to accelerate early-stage small molecule drug discovery. Our proprietary platform combines AI-driven molecule design with ultra-high-throughput screening to speed up hit identification and lead generation. What We Can Offer: Small Molecular Library Collections - Diversity Library: 53,359 compounds picked by experienced chemists from 26 million commercial compounds, offering broad coverage of chemical space with diverse scaffolds. - CRBN-Focused Molecular Glues library: 240,000 in-house designed compounds equipped with validated CRBN-binding warheads. Approximately 40% compounds in the library demonstrate confirmed binary binding to CRBN, offering significantly higher hit rates in later ternary assays. - Cyclic Peptide Library: A unique collection of cyclic peptides ranging from 5 to 10 amino acids in length with both sequence and physicochemical properties diversity. - CNS library: 14,000 compounds with Sp3-rich scaffolds for enhanced molecular diversity. These relatively rigid compounds are particularly suitable for CNS-target screening. - Covalent Library: A collection of diverse and Sp3-rich covalent compounds with the most demanded warhead types. 2D Molecular Generation Model: Our molecular generation model enables rapid exploration of chemical space based on your input fragment or scaffold. Whether you're optimizing a hit compound or seeking novel scaffolds, our 2DMG tool can generates diverse, drug-like structures to help on your project goals. Integrative chemistry services: We offer end-to-end chemistry support from hit identification to lead optimization, including: High-Throughput Virtual Screening (HTVS), Structure–Activity Relationship (SAR) Analysis, Computer-Aided Drug Design (CADD), Hit Similarity Searching etc. Contact Us: marketing@hit-chem.com